Introduction
Acute graft-versus-host disease (GVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Age, HLA match, response to initial treatment, maximum grade and initial grade of GVHD and GVHD prophylaxis are among factors reported to affect the survival of patients with acute GVHD. [1] [2] [3] [4] Recently, Lee et al., 5 reported that the factors identifiable at the onset of acute GVHD including laboratory parameters could predict the survival of patients with acute GVHD, and emphasized the importance of visceral involvement and a lower absolute lymphocyte count.
HSCT-associated thrombotic microangiopathy (TMA) is a potentially life-threatening complication of allogeneic HSCT, and is not associated with ADAMTS13 deficiency. 6, 7 Endothelial injury is likely to be the primary event in its pathogenesis. [8] [9] [10] Vascular endothelial cells have also been recognized as an important target for alloreactive cytotoxic T cells in the vascular rejection of solid organ transplants. 11 The use of calcineurin inhibitors, acute GVHD, cytokine release syndrome and infections, 12 may perpetuate the endothelial injury and enhance the appearance of TMA. Recent studies have shown acute GVHD is an important risk factor for TMA. [13] [14] [15] [16] However, to our knowledge, there are no reports that have objectively shown how TMA influences the survival of patients with acute GVHD.
Materials and methods

Patients and assessment of laboratory parameters
This study examined 674 consecutive patients who underwent allogeneic HSCT at the Catholic Hematopoietic Stem Cell Transplantation Center between January 2001 and December 2005. Of 188 patients (28%) who developed acute GVHD, 40 presented with localized skin GVHD and did not require systemic treatment. The remaining 148 patients who received systemic immunosuppressive treatment for acute GVHD were studied retrospectively. One physician studied blood smears for schistocytes. Ten fields with high-power of optical microscopy ( Â 1000) were examined and the mean number of schistocytes was used for the diagnosis of TMA. The institutional baseline of serum lactose dehydrogenase (LDH) was 472 IU/l. The Coombs test was evaluated for all patients who were expected to have TMA based on the schistocyte count and serum LDH. All patients were monitored for cytomegalovirus (CMV) at least twice weekly during admission, and when they visited the outpatient clinic. 17 Various clinical and laboratory data of the patients were retrieved from the database and the medical records of the hospital.
Transplantation procedures
Overall, 118 patients received bone marrow stem cells and 16 received granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSCs). On the basis of our previous experience of high-dose stem cell transplantation, 18, 19 14 patients received G-CSF-primed unmanipulated bone marrow plus PBSCs due to the risk of graft failure. The median number of infused CD34 þ and CD3 /kg (range ¼ 0.16-52.95), respectively. HLA matching was based on serologic typing for HLA-A, -B and -C antigens and molecular typing for HLA-DRB1. G-CSF was administered to all patients at a dose of 5 mg/kg subcutaneously per day from day þ 7 after the transplant until neutrophil recovery. The other general procedures of transplantation were performed as described in previous reports. 20, 21 Diagnosis and response assessment of GVHD and TMA A diagnosis of acute GVHD and chronic GVHD was made as previously described by consensus criteria 22 and the revised Seattle criteria. 23 The day of the onset of acute GVHD was defined as the date of initiation of systemic immunosuppressive treatment. All patients were classified according to the response of the primary treatment (mainly methylprednisolone 2 mg/kg) for acute GVHD on day þ 14. A complete response was defined as the complete resolution of all signs of GVHD. An incomplete response included a partial response and no response. A partial response involved a decrease in GVHD to a less severe grade, but there was still evidence of GVHD. No response indicated no change or the progression of GVHD to a more severe grading.
A diagnosis of TMA was made on the basis of the definition for TMA by BMT CTN: (1) Red blood cell fragmentation with X2 schistocytes per high-power field (HPF) on peripheral smear; (2) concurrent increased serum LDH above institutional baseline; (3) concurrent renal and/ or neurologic dysfunction without other explanations, where renal dysfunction is defined as either a doubling of serum creatinine from baseline, where baseline is the creatinine taken before hydration and just before initiation of the conditioning regimen or a 50% decrease in creatinine clearance from baseline; and (4) negative direct and indirect Coombs test results. 24 In order to clarify the clinical impact of TMA on the patients with acute GVHD, the severity of TMA was assessed as follows: definite (severe) TMA was defined as the presence of all 4 criteria by BMT CTN; probable (moderate) TMA was defined as the presence of 3 of the 4 criteria except for renal and/or neurologic dysfunction.
Assessment of prognostic factors
The following clinical parameters were assessed: the patient's age, gender, diagnosis, disease status at transplantation, donor type, HLA match, stem cell source, donor-recipient sex match, conditioning regimens, GVHD prophylaxis, initial grade of acute GVHD and the initial organ of involvement were variables at the onset of acute GVHD for initial treatment failure; the maximum grade of acute GVHD, the overall organ of involvement, the initial treatment failure, a CMV infection and the occurrence and severity of TMA were variables through the course of acute GVHD included for GVHD-specific survival and overall survival (OS). The initial and maximum grade of acute GVHD, as defined by the Consensus criteria, 22 were assessed from the clinical data available at the time of initiating the systemic immunosuppressive treatment and through the clinical course of acute GVHD, respectively. The initial and overall organs involved were also compared as skin versus visceral (with or without skin involvement).
The following laboratory parameters at the onset of acute GVHD were assessed as possible prognostic factors on the day of initiating the systemic immunosuppressive treatment for acute GVHD: serum levels of alanine aminotransferase (ALT), alkaline phosphate, albumin, peripheral blood absolute lymphocyte count and platelet count.
Statistical analysis
Three statistical end points were used to identify the variables that could affect the outcome of acute GVHD: initial treatment failure for the variables at the onset of acute GVHD, GVHD-specific survival and OS for the variables through the course of acute GVHD. Initial treatment failure was defined as an incomplete response at D þ 14 after the primary treatment, the recurrence of acute GVHD after an initial complete response or the patient's death due to acute GVHD-related complications while receiving the initial treatment. GVHD-specific survival was defined as the interval from the onset of acute GVHD to death due to acute or chronic GVHD-related complications without a relapse of the underlying malignancies after the onset of acute GVHD. Patients who relapsed with their underlying malignancies and who died of causes other than GVHD-related complications were censored at the time of the relapse and at the time of death, respectively. The OS was measured from the day of transplantation to death due to any cause.
Potential prognostic factors were analyzed using a w 2 or Fisher's exact test to predict the initial treatment failure, and Fisher's exact test was also used to compare the contribution of TMA to death between probable and definite TMA. The curves for the GVHD-specific survival and OS were plotted using the Kaplan-Meier method and compared using a log-rank test. For multivariate analysis, variables with a P-value o0.05, as determined by univariate analysis, were considered for entry into the model selection procedure on the basis of a multiple logistic regression model (initial treatment failure) or the Cox proportional hazards model (GVHD-specific survival and OS). Organ involvement was considered to be skin only versus visceral involvement rather than considering the involvement of each organ separately. The final models were selected using the forward conditional method with a predetermined risk of 0.1. The statistical analyses were performed using SPSS 11.5 software (SPSS, Chicago, IL, USA).
Results
Patients' characteristics
Of the 148 patients, 37 (25%) were diagnosed with acute GVHD on the basis of clinical findings, and 111 (75%) were diagnosed on the basis of clinical findings and histological examination. The median day of onset of acute GVHD was day 31 (range ¼ 10-86 days). Table 1 summarizes patients' characteristics. The median age was 33 years (range ¼ 15-52 years). Of the 148 patients, 43 (29%) were diagnosed with TMA. At the time of the transplant, 68% of patients had high-risk disease features, which included acute leukemia beyond the first remission, chronic myelogenous leukemia beyond the first chronic phase, high-risk myelodysplastic syndrome (international prognostic scoring system Xintermediate-2) and aplastic anemia, and/or paroxysmal nocturnal hemoglobinuria with a prior history of immunosuppressive treatment and/or longer disease duration (3 years or more) before the transplant. 25, 26 Table 2 summarizes the patients' clinical characteristics at the onset and through the course of acute GVHD. Initially, 124 patients were treated with methylprednisolone 2 mg/kg/day, 17 were treated with prednisone 1 mg/kg/day, and 7 were treated with mycophenolate mofetil 1 g/day with methylprednisolone 2 mg/kg/day. After the initial treatment, 103 patients (70%) showed a complete response. Of those who showed an incomplete response (n ¼ 45, 30%), 26 patients (18%) had a partial response and 19 patients (13%) had no response. Sixty-five patients (44%) experienced initial treatment failure, with one dying from acute GVHD while receiving initial treatment. Of the 19 patients with no response, secondary treatment options, which included extracorporeal photochemotherapy and/or monoclonal antibody, were used in 11 patients.
The median follow-up period of the surviving patients was 891 days (range ¼ 715-1067 days) after the onset of acute GVHD. Fifty-four patients died, resulting in a 3-year projected overall survival rate of 56%. Thirty-one patients died from acute or chronic GVHD-related complications, without a relapse of the underlying malignancy, after the onset of acute GVHD (GVHD-specific survival rate of 71%). Fifteen patients died owing to a relapse of the underlying malignancies, which occurred between 63 and 1203 days after the onset of acute GVHD. The other causes (n ¼ 8) of death were pneumonia and sepsis in three, delayed graft failure-related complications in two, and cerebrovascular accident and pulmonary hemorrhage and veno-occlusive disease in one each.
Prognostic factor analyses for acute GVHD Initial treatment failure. Univariate analysis revealed age (P ¼ 0.028), initial grade of acute GVHD (P ¼ 0.013), serum ALT level (Po0.001), serum alkaline phosphate level (Po0.001) and serum albumin level (P ¼ 0.007) to be significantly associated with initial treatment failure. Multivariate analysis revealed higher age (P ¼ 0.04), high ALT level (P ¼ 0.001), high alkaline phosphate level (P ¼ 0.027) and low albumin level (P ¼ 0.003) to be significant independent factors predicting a higher rate of initial treatment failure.
GVHD-specific survival. Univariate analysis revealed the donor type (P ¼ 0.019), stem cell source (P ¼ 0.021), HLA match (P ¼ 0.024), initial organ of involvement (P ¼ 0.003), overall organ of involvement (P ¼ 0.004), initial grade of acute GVHD (P ¼ 0.002), maximum grade of acute GVHD (Po0.001), serum ALT level (P ¼ 0.001), serum alkaline phosphate level (P ¼ 0.014), initial treatment failure (Po0.001), occurrence and severity of TMA (Po0.001) and CMV infection (P ¼ 0.006) to be significantly All patients received fludarabine-based reduced intensity regimens except for two of all patients and one TMA patient with aplastic anemia who received procarbazine instead of fludarabine. These patients were primarily those with leukemia who were either elderly or who had co-morbid diseases, aplastic anemia and paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome.
associated with GVHD-specific survival. Of these, multivariate analysis revealed peripheral blood stem cells, high serum ALT level, maximum grade of acute GVHD (III and IV), initial treatment failure and the occurrence and severity of TMA (Figure 1a ) to be significant independent factors associated with a shorter GVHD-specific survival (Table 3) .
Overall survival. Univariate analysis revealed age (P ¼ 0.004), HLA match (P ¼ 0.023), malignant disease or not (P ¼ 0.038), disease status at transplantation (P ¼ 0.031), initial organ of involvement (P ¼ 0.045), initial grade of acute GVHD (Po0.001), maximum grade of acute GVHD (Po0.001), initial treatment failure (Po0.001), occurrence and severity of TMA (Po0.001) and CMV infection (P ¼ 0.008) to be significantly associated with OS. Multivariate analysis revealed a high-risk disease status at transplantation, maximum grade of acute GVHD (III and IV), malignant disease, initial treatment failure and the occurrence and severity of TMA (Figure 1b ) to be significant independent factors associated with a shorter OS ( Table 3) .
Clinical characteristics of patients with TMA Among 43 patients who were diagnosed with TMA, 27 and 16 patients were classified as probable and definite TMA, respectively. The median day of the onset of probable and definite TMA after HSCT was day 53 (range ¼ 10-708 days), and 77% of these patients were diagnosed within the first 100 days after HSCT. Tables 1 and 2 summarize the characteristics of patients with probable and definite TMA at onset and through the course of acute GVHD. Table 4 describes the clinical characteristics at the onset of TMA. Of the 43 patients, 38 (72%) had concurrent acute GVHD (n ¼ 31) and chronic GVHD (n ¼ 7). CMV infection (n ¼ 28) and other co-infections (n ¼ 9), which included fungal pneumonia (n ¼ 4), pneumocystis carinii pneumonia (n ¼ 2), viral pneumonia (n ¼ 2) and bacteremia (n ¼ 1), also developed during the course of TMA. The median maximum number of schistocytes and the maximum serum LDH level were 3 (range ¼ 2-25) and 1123 IU/l (range ¼ 418-15 810), respectively. Fifteen (20%) and 4 patients (5%) had a renal and neurologic dysfunction, respectively, which was the reason for the diagnosis of definite TMA. Three patients had both. The initial treatment strategy was dose reduction or complete withdrawal of calcineurin inhibitors and transfusion of cryoprecipitate-poor plasma. Overall, 16 patients were treated with total plasma exchange (TPE) for TMA after the failure of prior therapy, which included 5 out of 27 patients with probable TMA and 11 out of 16 patients with definite TMA, and 3 out of 5 patients with definite TMA who were not treated with TPE died before starting TPE from a hemorrhage or infection. Among the 5 patients with probable TMA who were treated with TPE, 4 (80%) showed complete resolution of the TMA, whereas only 3 (27%) out of 11 patients with definite TMA showed complete resolution.
Among all 43 patients with TMA, 27 died after being diagnosed with TMA (probable TMA, n ¼ 14; definite Table 2 Clinical characteristics at the onset and through the course of acute GVHD
Characteristics
All patients (n ¼ 148) (%) Abbreviations: CMV ¼ cytomegalovirus; GVHD ¼ graft-versus-host disease; TMA ¼ thrombotic microangiopathy. a TMA patients included those with probable TMA and definite TMA. b Eleven cases of all patients and four cases of TMA patients were upper gut GVHD. c About a quarter of patients each had elevated alanine aminotransferase X100 IU/l, elevated serum alkaline phosphatase X274 IU/l, hypoalbuminemia o3.43 g/dl and lymphocytopenia o500/ml.
TMA, n ¼ 13), whereas 16 patients were alive. Among the 27 patients, TMA was a contributing cause of death in 15 patients (56%), which included 4 with probable TMA and 11 with definite TMA, and the other 12 patients (44%) died of other causes after the resolution of TMA. The contribution of TMA to death was more prominent in definite TMA (11 of 13, 85%) than in probable TMA (4 of 14, 29%) (P ¼ 0.006), which was shown in Table 5 . Other conditions combined with TMA-associated death were GVHD, infection, hemorrhage and multiorgan failure syndrome (Table 4) .
Discussion
TMA is recognized as one of the most severe complications associated with GVHD after allogeneic HSCT. Given the fact that endothelium damage can be induced by various Days after acute GVHD 1500.00 2000.00 2500.00 0.00 500.00 1000.00
Days after HSCT 1500.00 2000.00 2500.00
No TMA No TMA Probable TMA Probable TMA Definite TMA Definite TMA P < 0.001 P < 0.001 Figure 1 Impact of the severity of TMA on the probability of GVHD-specific survival (a) and OS (b) in patients with acute GVHD (Kaplan-Meier curves). Log-rank tests showed that P-values were lower than 0.001 in both (a and b) . GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; OS, overall survival; TMA, thrombotic microangiopathy. factors, 12 such as the conditioning regimen, cytokine cascades, the use of calcineurin inhibitors and infections such as CMV or fungi, an early diagnosis and proper management of TMA after the occurrence of acute GVHD may be crucial for improving the transplant outcome. The predictive value of the maximum grade of acute GVHD for the survival of patients with acute GVHD has already been demonstrated by an analysis of the long-term outcome of 197 patients with acute GVHD. 1 A poor response to the initial treatment was also reported to be associated with a poorer survival of patients with acute GVHD. 2, 4, 27 Our data showed that both the maximum grade of acute GVHD and initial treatment failure were factors predicting a shorter GVHD-specific survival and a shorter OS. Notably, the occurrence of TMA, in addition to the maximum grade of acute GVHD and initial treatment failure, was an independent factor associated with a shorter GVHD-specific survival and shorter OS, which suggests that the occurrence of TMA may contribute to higher transplant-related mortality and therefore shorter survival. To our knowledge, there are no reports that have objectively shown how TMA influences the survival of patients with acute GVHD, although recent studies have shown that acute GVHD is an important risk factor for TMA. [13] [14] [15] [16] The reported incidence of TMA varies from 0.5 to 76%. [13] [14] [15] [16] [28] [29] [30] [31] [32] [33] [34] A recent literature review identified 447 (8.2%) cases of TMA, with a median mortality of 75% within 3 months of the diagnosis. 35 The large variability in the published incidence is due to the fact that there are no uniformly accepted diagnostic criteria for this clinical syndrome. Recently, in an effort to develop a consensus formulation of criteria for diagnosing clinically significant TMA, the BMT CTN Committee on Transplant Toxicity 24 and the International Working Group (IWG), formed by the European Group for Blood and Marrow Transplantation (EBMT) and the European LeukemiaNet, 36 proposed a definition for TMA, with some differences. The BMT CTN defined TMA as an increased number of schistocytes and elevated LDH, concurrent renal and/or neurologic dysfunction and negative Coombs test results. 24 On the other hand, the IWG defined TMA by adding prolonged or progressive thrombocytopenia, a decrease in the hemoglobin and serum haptoglobin concentration instead of concurrent renal and/or neurologic dysfunction and negative Coombs test results. 36 This study adopted BMT CTN Toxicity Committee Consensus Definition for TMA for definite TMA, as a most severe form of TMA. However, considering the special conditions of TMA in that the causes of nephropathy are manifold and neurologic abnormalities are less prominent in TMA than in de novo thrombotic thrombocytopenia purpura, as the IWG indicated, 36 another category of TMA, probable TMA, was made that had none of the features of nephropathy and neurologic abnormalities of definite TMA. Although a diagnosis of TMA is unclear, it may be important to recognize it before TMA can have harmful effects on some of the parenchyma functions, which leads to so-called multiorgan failure. In this perspective, the present study demonstrated the different clinical significance of each type of TMA. Notably, probable TMA as well as definite TMA was significantly associated with GVHD-specific survival and OS, which suggests that probable TMA (increased LDH and schistocytes (X2/HPF) without nephropathy and neurologic abnormalities) is clinically significant and needs to be included in the diagnostic criteria for TMA. However, further studies including patients without acute GVHD will be needed to confirm this.
A recent review of TMA emphasized that among the patients who died after being diagnosed with TMA and for whom the cause of death was reported, TMA is rarely considered to be a contributing cause of death. 37 A recent case series including patients undergoing allogeneic HSCT reported TMA to be a factor contributing to or causing Fisher's exact test; P ¼ 0.006.
death in 1 out of 19 (5%), 33 2 out of 13 (15%), 14 none of six (0%), 34 and 4 out of 19 (21%) patients. 15 On the other hand, in this study, TMA was a contributing cause in 15 out of 27 (56%) patients who died after being diagnosed with TMA, which revealed the clinical impact of TMA in patients with acute GVHD. Notably, TMA was a contributing cause of death in more patients with definite TMA (11 of 13, 85%) than with probable TMA (4 of 14, 29%), which suggests that TMA should be treated at an early stage before it develops into definite TMA, which has nephropathy as a major feature, with or without neurologic abnormalities. This observation is consistent with a survey carried out among EBMT centers, which revealed the absence of nephropathy to be the only factor predicting the resolution of TMA. 31 In summary, the present study shows the prognostic factors associated with survival of patients with acute GVHD and reveals the negative impact of TMA on the course of acute GVHD.
